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Abstract
Background: Empirical support for cognitive behavioral therapy (CBT) for treating Japanese patients with major 
depression is lacking, therefore, a feasibility study of CBT for depression in Japanese clinical settings is urgently required.
Findings: A culturally adapted, 16-week manualized individual CBT program for Japanese patients with major 
depressive disorder was developed. A total of 27 patients with major depression were enrolled in a single-group study 
with the purpose of testing the feasibility of the program. Twenty six patients (96%) completed the study. The mean 
total score on the Beck Depression Inventory-II (BDI-II) for all patients (Intention-to-treat sample) improved from 32.6 to 
11.7, with a mean change of 20.8 (95% confidence interval: 17.0 to 24.8). Within-group effect size at the endpoint 
assessment was 2.64 (Cohen's d). Twenty-one patients (77.7%) showed treatment response and 17 patients (63.0%) 
achieved remission at the end of the program. Significant improvement was observed in measurement of subjective 
and objective depression severity (assessed by BDI-II, Quick Inventory of Depressive Symptomatology-Self Rated, and 
Hamilton Depression Rating Scale), dysfunctional attitude (assessed by Dysfunctional Attitude Scale), global 
functioning (assessed by Global Assessment of Functioning of DSM-IV) and subjective well-being (assessed by WHO 
Subjective Well-being Inventory) (all p values < 0.001).
Conclusions: Our manualized treatment comprised of a 16-week individual CBT program for major depression 
appears feasible and may achieve favorable treatment outcomes among Japanese patients with major depression. 
Further research involving a larger sample in a randomized, controlled trial design is warranted.
Trial registration: UMIN-CTR UMIN000002542.
Background
The 12-month prevalence of mood disorder in Japan is
3.1% and is associated with higher incidence of suicide
and marked economic morbidity [1]. Therefore, it is
important for clinicians as well as policy makers to estab-
lish quality treatment programs for major depression.
Thanks to the robust research evidence on its efficacy
for treating depression [2-4], cognitive behavioral therapy
(CBT) has been drawing considerable attention among
the general public [5], as well as among clinicians, in
Japan. The number of members of the Japanese Associa-
tion for Cognitive Therapy (JACT) has been quadrupled
from approximately 300 in 2001 to 1400 in 2009 [6].
Despite these developments, CBT has yet to be adopted
in daily clinical practice in Japan. A recent nationwide
s u rv e y  d e m o n s t r a t e d  t h a t  o n l y  2 8 %  o f  a l l  t h e  m e d i c a l
facilities in Japan were satisfied with their delivery of psy-
chotherapy, and CBT was listed as the 'most in need' psy-
chotherapy among the various types of psychotherapy
[7]. Insufficient provision of CBT in daily practice is
largely attributable to lack of empirical support for CBT
among Japanese depression patients. The models and
therapeutic components of CBT were mostly developed
based on Western conceptualizations of depression, and
most studies demonstrating the efficacy of CBT were
conducted in Europe and North America [2,3]. Empirical
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support for CBT in Japanese clinical settings is still
required.
Literature review and our clinical experience suggest
that Japanese patients generally prefer directive, problem-
solving approaches, where the therapists are required to
make the therapy more structured and solution-focused
[8,9]. Compared with Western cultures, more emphasis is
placed on interpersonal relationships than self-fulfillment
or self-development [10]. There are needs for consider-
ation of family as an essential part of the treatment. The
Japanese culture has formerly been family- and commu-
nity- oriented, but recently there is a shifting trend for
increasing emphasis on individuality. These issues should
be comprehensively addressed during the therapy.
On the basis of this information, we developed an indi-
vidual CBT program for treating Japanese patients with
depression. The program was constructed upon the
model developed by Beck et al. [11], with some adapta-
tion to address the cultural characteristics of the Japanese
patients. The treatment manual is downloadable from the
website of the Japanese Ministry of Health, Labor and
Welfare [12]. The overview of the program is shown in
the Table 1. Problem-solving techniques and interper-
sonal issues were emphasized and the therapists were
encouraged to refer to the relevant chapters whenever
considered necessary. Furthermore, the therapists were
encouraged to give feedbacks to the patients about the
case conceptualization in the earlier phase of the therapy.
To the best of our knowledge, no study to date in Japan
has examined the feasibility of a manualized individual
CBT for depression. Therefore, the present pragmatic
study aimed to test feasibility of our manualized CBT
program for major depressive disorder in outpatient set-
tings in Japan. We examined its feasibility by exploring
the acceptability of intervention with treatment providers
and patients, rate of complete/dropout of treatment,
resources required to carry out the intervention and
effect of treatment.
Methods
Participants
Participants were the ambulatory patients aged 18 - 60
years, who met the criteria for a primary diagnosis of cur-
rent Major Depressive Disorder (MDD) according to the
Structured Clinical Interview for Axis-I DSM-IV Disor-
ders [13]. The exclusion criteria were active suicidal
intent, unstable physical conditions, or antisocial person-
ality disorder. The participants were recruited through
referral by psychiatrists at the participating study sites
between April 2004 and August 2007. The study sites
consisted of two psychiatric hospitals, two university hos-
pitals and one psychiatric clinic in Tokyo. These sites
were selected because they had expertise in both treating
depression and providing psychotherapy.
Interventions
The individual CBT program described above was pro-
vided on a weekly or fortnightly basis. The therapy com-
prised of 16 sessions, with each session lasting for 50
minutes. The therapists were allowed either to extend the
therapy to a maximum of 20 sessions, or to abort the pro-
gram after the seventh session upon agreement between
the patient and the therapist, provided that the Beck
Depression Inventory (BDI-II) had fallen to the score of
13 or below (remission). The therapists were psychiatrists
or master's-degree clinical psychologists with over 3-year
c li nical  e x pe ri enc e  and wit h e x pe rie nc e  in  CB T  of  1-5
years. The therapists participated in a two-day workshop
to ensure treatment fidelity, and afterward participated
two-hour fortnightly group supervision sessions. The
group supervision was lead by one of our co-authors
(YO), the founder of the JACT and a fellow of Academy of
Cognitive Therapy [14], facilitating discussion of thera-
peutic difficulties and impasses, providing skills acquisi-
tion, and peer support and interaction. The supervisee-
therapists were asked to make presentation regarding
changes in the BDI-II scores, treatment process, case for-
mulation, and treatment planning. A therapist's self-
report check list outlining the key elements of the treat-
ment, which was originally developed for this study, was
used to ensure treatment adherence.
The patients were allowed to continue the antidepres-
sants and anxiolytics that had been prescribed at the
baseline throughout the study.
Outcome measures
The primary outcome measure was the patients' subjec-
tive severity of depression which was assessed using the
Beck Depression Inventory (BDI-II) [15]. The severity of
depression is categorized based on the following BDI-II
scores in Japanese samples: a score of 13 or less as mini-
mal (or remission); 14 to19 as mild; 20 to 28 as moderate;
29 or greater as severe [16].
The secondary outcomes included the 17-item Hamil-
ton Rating Scale for Depression (HAMD-17) [17], the
Global Assessment of Functioning (GAF) scale of DSM-
IV [18], the World Health Organization Subjective Well-
being Inventory (SUBI)[19], and the 24-item Dysfunc-
tional Attitude Scale (DAS-24) [20], with the purposes of
assessing objective depression severity, global function-
ing, subjective well-being, and dysfunctional attitudes,
respectively. The 16-item Quick Inventory of Depressive
Symptomatology Self-Rated (QIDS-SR) [21] was also
administered in order to facilitate the comparison of the
results with a variety of past studies.
The BDI-II was administered at each session, and other
measurements were administered at pre- and post- treat-
ment. The HAMD-17 was administered by the study
therapists. A training workshop was conducted in orderFujisawa et al. BMC Research Notes 2010, 3:160
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to ensure the inter-rater reliability of the measures. The
raters were certified when 80% accuracy was achieved, as
referring the demonstration videos. The measures were
not blinded to the treating clinician, because monitoring
of social and psychological status was considered to be an
essential part of the CBT program.
Statistical analysis
The analysis was by intention-to-treat (ITT), and for
non-completers, the last obtained data were carried for-
ward into the endpoint assessment. The baseline and
endpoint scores on the outcome measures were com-
pared using t tests. Regarding the BDI-II, changes from
the baseline at each visit was analyzed using repeated
ANOVA. The cutoff point for remission was defined as
an endpoint BDI-II score of 13 or less [16], and treatment
response was defined as a reduction of 50% on the BDI-II
[22]. Regarding the HAMD-17, remission was defined as
an endpoint total score of 7 or less, and treatment
response was defined as a reduction of at least 50% [23].
All statistical tests were two-tailed, and an alpha value
of less than 0.05 was considered statistically significant.
Within-group effect sizes were computed as d, the stan-
dard mean difference. Cohen [24] defines effect sizes as
small (d = 0.20), medium (d = 0.50), and large (d = 0.80).
All data analyses were conducted using SPSS version
16.0J software (SPSS Inc., Chicago, IL, USA).
Ethical considerations
All participants gave written informed consent after
receiving a full description of the study. The protocol of
this study was approved by the Ethics Committee at each
study site, and was registered in the national UMIN Clin-
ical Trials Registry (ID: UMIN000002542).
Results
Treatment acceptability by the therapists
All the participating therapists completed the training
program and were able to adhere to the treatment proto-
col under the supervision.
Baseline data
A total of 27 who met the inclusion criteria patients were
referred to the study. All of them submitted a written
informed consent and entered the study. Of those, 19
patients were diagnosed with recurrent MDD and the
remainders were diagnosed with single episode MDD.
Three patients had one of the following concurrent psy-
chiatric disorders: panic disorder, borderline personality
disorder and schizotypal personality disorder. Other clin-
ical characteristics of the participants are shown in Table
2.
Table 1: Overview of stages in therapy.
Stage Session Purpose Agenda Tools/homework
11  -  2 B u i l d i n g  a l l i a n c e
Psychoeducation
Motivate the patient
Socializing the patient
Review on symptoms, course of illness and 
developmental history
Psychoeducation on depression, cognitive models, 
structure of the therapy
"What is depression?"
"What is CBT?"
2 3 - 4 Case conceptualization
Goal setting
Activating the patient
Collaboratively setting treatment goals
Activity scheduling
Brief feedback on case conceptualization
Problem list
Activity record
3 5 - 6 Identifying mood and 
automatic thoughts
Dysfunctional thought record (triple column) "How to identify your moods 
and thoughts"
4 7 - 12 Testing automatic thoughts
(Optional - dissolving 
interpersonal conflicts/
problem solving)
Dysfunctional thought record (seven columns)
(Optional module - assertive training/problem 
solving)
"How to balance your 
thoughts"
Interpersonal module
Problem-solving module
51 3  -  1 4 I d e n t i f y i n g  s c h e m a s D ysfunctional thought record
Discussion on schemas
"Rules of your mind"
6 15 - 16 Termination
Relapse prevention
Review of the therapy
Relapse prevention
Preparation for booster sessions
"Upon ending your therapy"Fujisawa et al. BMC Research Notes 2010, 3:160
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Treatment and dropout
Twenty-six patients (96%) completed the program. One
female patient with borderline personality disorder
dropped out at the fifth session. The mean number of
attended CBT sessions was 15.3 (SD = 2.8). The flow of
participants through each stage is shown in Figure 1.
Primary Outcome of the Program
A significant improvement on the BDI-II scores was
observed from the baseline to week 16 (p < 0.001) (Table
3). The mean total score of BDI-II decreased from 32.6 to
11.7, which corresponds to clinical improvement from
severe to minimal depression. Twenty one patients
(77.7%) were judged to be treatment responders and 17
patients (63.0%) were judged to be remitters. The mean
score on the BDI-II continuously decreased as sessions
proceeded and it became significantly lower after the fifth
session (p < 0.05) (Figure 2).
Secondary Outcomes of the Program
Table 3 shows the means and standard deviations of all
other measures at pre- and post-treatment. Depression
severity measures (HAMD-17 and QIDS-SR), dysfunc-
tional attitudes (DAS-24), subjective well-being (SUBI)
and social functioning (GAF) showed significant
improvement after the program (all p values < 0.001). On
Table 2: Clinical characteristics of participants.
Characteristics n %
Socioeconomic characteristics
Gender
Female 18 66.7
Male 9 33.3
Marital status
Single 13 48.2
Married or cohabitant 10 37.0
Divorced 4 14.8
Education
Finished tertiary education 12 44.4
Employment
Employed 20 74.1
Housewife 3 11.1
Unemployed 4 14.8
Clinical characteristics
Major Depressive Disorder, single 
episode
82 9 . 7
Major Depressive Disorder, recurrent 
episode
19 70.3
Concomitant antidepressants or 
anxiolytics use
Yes 22 81.5
No 5 18.5
Mean SD
Age (years) 38.5 9.5
Duration of current depression episode 
(years)
5.6 4.3
Range (years) 1 to 13Fujisawa et al. BMC Research Notes 2010, 3:160
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the HAMD-17, 12 patients (44%) were judged to be treat-
ment responders and 9 patients (33%) were judged to be
remitters.
Discussion
The result of this 16-week individual CBT program offers
preliminary optimism for applying CBT for treating
major depressive disorder in Japan. Favorable outcomes
were demonstrated in regard to excellent acceptability by
both of the treatment providers and the patients, low
dropout rate, and improvement in pervasive outcome
measures. The additional resources to provide the treat-
ment are minimal, except that the therapists need formal
training for CBT under regular supervision.
The proportions of the patients who remitted and/or
responded are comparable with those of the Sequenced
Treatment Alternatives to Relieve Depression study
(STAR*D) [25], one of the largest pragmatic clinical trials
for major depression involving CBT, which established a
benchmark for acceptable dropout rate and effectiveness.
The dropout rate in the STAR*D was 9.2% for its CBT
augmentation upon medication arm, whereas the drop-
out rate in the present study was 3.7%. The STAR*D
reported a response rate of 35.4% and a remission rate of
30.8% on the self-rating measure, whereas the present
study showed a response rate of 77.7% and a remission
rate of 63.0%. The effect size of 2.64 observed for the
BDI-II is comparable with the results of past CBT studies,
in which effect sizes of 1.82 - 2.43 were reported [26,27].
However, we must be cautious about the interpretation
of our data, because the present study contains the fol-
lowing limitations. First, this was a single-arm study
without a control group; therefore we cannot be conclu-
sive that our CBT program was effective. The Hawthorne
effect, which is typical seen in uncontrolled studies, can-
not be denied in our study design, and therefore, future
randomized controlled study is required. Although the
effect size was high, it might have been inflated due to the
lack of control group [28]. Second, the study involved a
limited number of patients. The distribution of the par-
ticipating patients was somewhat skewed from the distri-
bution of the national statistics. Relatively smaller
proportion of patients who were widowed or divorced,
and who were unemployed participated in this study.
Third, CBT was delivered by the physicians in charge of
their care for most of the participants; therefore, the pos-
itive therapeutic bonds formed prior to the study may
have contributed to the low dropout rate and high
improvement rate. Fourth, the treatment adherence was
monitored based on the therapists' presentation and ther-
apy record, not by audio-taped record. Finally, the
HAMD-17 was evaluated by the therapists and its reli-
ability is compromised.
These limitations may be off-set by the following fac-
tors. First, we employed a self-report measure (BDI-II) as
the primary outcome. Although the participants may
have rate their severity of depression lower due to bias
towards the treating clinician, submitting a self-report
measure of depression severity is an essential part of CBT
program. Second, statistically significant improvement
was demonstrated on multiple measures, with the
patients' self-ratings showing a similar magnitude of
improvement as compared with the clinician-rated mea-
sures. Third, baseline severity of depression ranged from
mild to severe depression, which is considered to be rep-
resentative of the general Japanese clinical population.
Fourth, the study site comprised of facilities of different
characteristics (including university hospital, mental hos-
pital and mental clinic).
The favorable outcome for CBT observed in this study
is an important first step for the implementation of CBT
in Japanese clinical settings. It may also have a potential
impact to therapists outside Japan who treat depression
Figure 1 Flow of the participants. CBT: cognitive behavioral therapy. 
ITT: intent-to-treat. Min: minimum. Max: maximum.
Assessed for eligibility
(n = 27)
Allocated to CBT (n = 27)
Received CBT (n = 27)
Did not receive CBT (n = 0)
Study sites (n = 5) 
performing CBT
Number of patients 
Excluded (n = 0)
p
treated by each site
(mean=5, min=2, 
max=13)
Early treatment 
discontinuation (n = 1)
Analyzed  (n =27)
(ITT analysis)Fujisawa et al. BMC Research Notes 2010, 3:160
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patients of Asian ethnicity. To date, clinical trials of CBT
for depression among Asian population have been only
sporadically reported; therefore, our report provides use-
ful informative findings in this issue. Our findings sup-
port the applicability of CBT for various cultures,
consistent with findings in non-Western studies from
Hong Kong [29] and Korea [30].
Conclusions
It is indicated that this cognitive behavioral intervention
can lead to positive outcomes in treating Japanese
patients with major depressive disorder, although further
controlled trials which address the limitations of this
study are required.
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Table 3: Comparison of pre- and post-treatment scores of outcome measures.
Baseline Endpoint % 
improvement
Cohen's d
Outcome Measures Mean SD Mean SD
BDI-II 32.6 9.5 11.7* 5.9 64.1 2.64
HAMD-17 24.3 7.4 8.1* 3.4 66.6 2.81
QIDS-SR 21.3 7.1 9.4* 3.4 19.9 2.14
GAF 46.1 9.6 73.2* 8.5 57.8 2.99
DAS-24 106.4 29.6 85.5* 14.7 19.9 0.89
SUBI - health subscale 38.4 6.4 38.3* 5.0 20.8 0.02
SUBI - fatigue subscale 32.6 9.5 46.4* 5.4 64.1 1.79
Intent-to-treat sample, Last-observation-carried forward analysis
BDI-II: Beck Depression Inventory-II score
HAMD: Hamilton Depression Rating Scale
QIDS-SR: Quick Inventory of Depressive Symptomatology -Self Rated
GAF: Global Assessment of Functioning of DSM-IV
DAS: Dysfunctional Attitude Scale
SUBI: WHO Subjective Well-being Inventory
* p < 0.001
Figure 2 Changes over time in mean Beck Depression Inventory-
II scores. Intent-to-treat sample. Comparison with baseline score, *p < 
0.05, **p < 0.01. Bars: 95%Confidence Interval.
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